Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2019

View Archived Issues

Congenital neurodevelopmental disorders caused by de novo variants of TAOK1

Macrocyclic peptide HiP-8 selectively inhibits active hepatocyte growth factor

NOX1 inhibitor, alone or combined with checkpoint inhibitors, halts colorectal cancer growth

How toxoplasmosis parasites get around

Editing modifiers, not disease gene, improves dystrophy symptoms

First patient randomized in phase II study of AM-125 for the treatment of acute vertigo

INO-5151 to be evaluated in innovative cancer combination trial

First results presented from phase Ib proof-of-concept study of KSI-301

EDP-305 demonstrates preferential penetration of NASH organs

In vivo disposition kinetics of CTI-1601

Advax adjuvant favorably enhances immunogenicity of HBVIT in phase I/II study

miR-34a involved in drug-induced epithelial-mesenchymal transition in lung cells

Eisai reports death in phase I study of E-2082

Chipscreen Biosciences presents clinical data for chiglitazar in type 2 diabetes

FDA approves Nubeqa for non-metastatic castration-resistant prostate cancer

Mezzion reports promising topline data from phase III FUEL study of udenafil

Bexion completes end-of-phase I meeting with FDA for BXQ-350

Phase II study of ATI-501 in alopecia areata meets primary endpoint

Shuttle Pharmaceuticals presents HDAC6 inhibitors

Centaurus Therapeutics patents dihydroceramide desaturase inhibitors

Almac Discovery synthesizes Wee1 inhibitors

Zeno Royalties & Milestones describes new Bcl-2 inhibitors

Genentech and Roche patent JAK1 inhibitors for asthma

Aravive reports antitumor activity in phase Ib trial of AVB-500 in platinum-resistant ovarian cancer

Translate Bio reports interim data from phase I/II trial of MRT-5005 in cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...